Nanosphere, Inc.  

(Public, NASDAQ:NSPH)   Watch this stock  
Find more results for NSPH
0.00 (0.00%)
Jul 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 2.75 - 31.00
Open     -
Vol / Avg. 0.00/98,713.00
Mkt cap 17.36M
P/E     -
Div/yield     -
EPS -8.24
Shares 5.86M
Beta 3.78
Inst. own 15%
Aug 4, 2015
Q2 2015 Nanosphere Inc Earnings Release (Estimated) Add to calendar
May 12, 2015
Q1 2015 Nanosphere Inc Earnings Call - Webcast
May 11, 2015
Q1 2015 Nanosphere Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -163.12% -273.41%
Operating margin -156.93% -263.75%
EBITD margin - -250.68%
Return on average assets -77.27% -76.76%
Return on average equity -130.71% -111.93%
Employees 169 -
CDP Score - -


4088 Commercial Avenue
United States - Map
+1-847-4009000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Nanosphere, Inc. is engaged in developing, manufacturing and marketing an advanced molecular diagnostics platform, the Verigene System, which enables genomic and protein testing on a single platform. The Company's nanoparticle technology provides the solution to run multiple tests simultaneously on the same sample. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides for multiple tests to be performed on a single platform, including both genomic and protein assays, from a single sample. The Verigene System is comprised of a microfluidics processor, a touchscreen reader, certain disposable consumables used in sample preparation, target amplification and test cartridges. The Company is focused on the infectious disease diagnostics market.

Officers and directors

Michael K. McGarrity President, Chief Executive Officer, Director
Age: 52
Bio & Compensation  - Reuters
Farzana Moinuddin Principal Financial Officer, Interim Accounting Officer
Bio & Compensation  - Reuters
Kenneth Bahk Ph.D. Chief Strategy Officer
Age: 41
Bio & Compensation  - Reuters
Kristopher A. Wood Director
Age: 43
Bio & Compensation  - Reuters
Gene S. Cartwright Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Andre de Bruin Independent Director
Age: 68
Bio & Compensation  - Reuters
Erik Holmlin Ph.D. Independent Director
Age: 47
Bio & Compensation  - Reuters
Lorin Jeffry Randall Independent Director
Age: 71
Bio & Compensation  - Reuters